What is the market cap of MoonLake Therapeutics?
MoonLake Therapeutics, a clinical-stage biotechnology company, has a market cap of approximately $32.84 million as of October 2023. The company's main drug candidate, Sonelokimab, is a novel nano-antibody targeting IL-17A and IL-17F, showing promising results in clinical trials for inflammatory diseases.